+1.212.901.8009 sclassen@alzdiscovery.org

19th INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY
September 17-18, 2018 • Jersey City, NJ (across from NYC on the Hudson)

Preliminary Program

All sessions will be held at the Hyatt Regency Jersey City (Manhattan Ballroom, 9th Floor).

Sunday, September 16

5:00–7:00pm On-site Pre-registration

Monday, September 17

8:00am–5:30pmRegistration
8:00–8:30amContinental Breakfast
8:30–8:50Welcome & Opening Presentation: Setting the Stage for New Alzheimer’s Disease Therapeutics
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation [bio]
8:50–9:20KEYNOTE: Challenges in CNS Clinical Trials
Michael Gold, MD, MS—AbbVie [bio]
9:20-9:30Discussion and Q&A
Session I: GENE THERAPY AND ALTERNATIVE MODALITIES FOR NEURODEGENERATIVE DISEASES
Chair: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
9:30–9:35Session Overview: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation [bio]
9:35–9:55RNAi-based Modulation of Gene Expression in CNS: Implications for Alzheimer’s Disease
Anastasia Khvorova, PhD—RNA Therapeutics Institute, University of Massachusetts Medical School [bio]
9:55–10:05Q&A
10:05–10:25 Translation to the Clinic of AAVrh.10-mediated Delivery to the CNS of the Apolipoprotein E2 Gene for Treatment of Alzheimer's Disease
Ronald Crystal, MD—Weill Cornell Medical College [bio]
10:25–10:35Q&A
10:35–11:00EXHIBITOR SESSION BREAK
11:00–11:20WVE-3972-01, an Investigational Stereopure Antisense Oligonucleotide, Preferentially Knocks Down G4C2 Repeat-Containing C9ORF72 Transcripts
Yuanjing Liu, PhD—Wave Life Science [bio]
11:20–11:30Q&A
11:30–11:50Safety and Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Patients with Mild Alzheimer's Disease
Anthony Oliva, PhD—Longeveron LLC [bio]
11:50am–12:00pmQ&A
12:00-12:30POSTER SESSION
12:30–1:35
LUNCH
Session II: NOVEL SMALL MOLECULE APPROACHES TO DEMENTIA
Chair: Yuko Hara, PhD—Alzheimer’s Drug Discovery Foundation
1:35–1:40Session Overview: Yuko Hara, PhD—Alzheimer’s Drug Discovery Foundation [bio]
1:40–2:00Development of Small Molecule Activators of Glutamate Transporter EAAT2 Translation for Alzheimer's Disease
Chien-liang Glenn Lin, PhD—Ohio State University [bio]
ADDF/Harrington Scholar
2:00–2:10Q&A
2:10–2:30Targeting Inflammatory Resolution as Preventative and Therapeutic Strategies for Alzheimer's Disease
Masashi Kitazawa, PhD—University of California, Irvine [bio]
2:30–2:40Q&A
2:40–3:00Development of Small Molecule Mitochondria-targeted Therapeutic for Alzheimer's Disease
Eugenia Trushina, PhD—Mayo Clinic [bio]
3:00–3:10Q&A
3:10–3:40EXHIBITOR SESSION BREAK
3:40–4:00Targeting Mitochondrial TDP-43 to Treat Alzheimer's Disease
Xinglong Wang, PhD—Case Western Reserve University [bio]
ADDF/Association for Frontotemporal Degeneration Partnership Program
4:00–4:10Q&A
4:10–4:30 mGlu5 PAMs for the Treatment of Alzheimer's Disease
Jerri Rook, PhD—Vanderbilt Center of Neuroscience Drug Discovery [bio]
4:30–4:40Q&A
4:40–5:00Exploratory Optimization of New CX3CR1 Modulators for the Treatment of Alzheimer's Disease
Mary Hamby, PhD—The Neurodegeneration Consortium, MD Anderson Cancer Center[bio]
5:00–5:10Q&A
5:10–5:20Closing Remarks and Announcement of Young Investigator Scholarships
Nicole Bjorklund, PhD—Alzheimer’s Drug Discovery Foundation
5:20–7:00NETWORKING RECEPTION

Tuesday, September 18

8:00–8:30amContinental Breakfast
8:30–8:35Day 2 Opening Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
8:35–9:05 KEYNOTE: FNIH Biomarker Initiatives in Neuroscience—Consortium Efforts in the Development of Biomarkers for Drug Development
Rosa Canet-Aviles, PhD—Foundation for the National Institutes of Health (FNIH) [bio]
9:05-9:15Discussion and Q&A
Session III: BIOMARKERS
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
9:15–9:20 Session Overview: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation [bio]
9:20–9:40Epigenetic Mechanisms in Human Memory: Quantification by Non-invasive PET Imaging in the Aged Brain
Jacob Hooker, PhD—Massachusetts General Hospital [bio]
9:40–9:50Q&A
9:50–10:10Abeta Complexes and Other Proteins Targets from Blood as Early Indicators of Amyloid Accumulation in the Brain
Blaine Roberts, MD—Florey Institute of Neuroscience and Mental Health [bio]
10:10–10:20Q&A
10:20–10:50EXHIBITOR SESSION BREAK
10:50–11:10Quantitative Assessment by Mass Spectrometry of Amyloid beta 42 and 40 in Plasma as a Peripheral Indicator of Brain Amyloidosis
Tim West, PhD—C2N Diagnostics[bio]
ADDF/Association for Frontotemporal Degeneration Partnership Program
11:10–11:20Q&A
11:20–11:40Isolation of Neurally-Derived Exosomes from Blood for the Diagnosis and Staging of Sporadic Alzheimer’s Disease
Diana Cha, PhD—Brigham & Women's Hospital [bio]
11:40–11:50Q&A
11:50am–12:35pmEMERGING CONCEPTS: DATA BLITZ
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
Young Investigator #1: Pierre-François Meyer, PhD (c)—McGill University
Young Investigator #2: Kevin Clayton, PhD (c)—Boston University School of Medicine
Young Investigator #3: Alexander Conley, PhD—Vanderbilt University Medical Center
12:35–1:35LUNCH AND POSTER SESSION
All poster presenters should stand by their poster from 1:05-1:35PM
Session IV: CLINICAL TRIALS
Chair: Nicholas McKeehan—Alzheimer’s Drug Discovery Foundation
1:35–1:40Session Overview: Nicholas McKeehan—Alzheimer’s Drug Discovery Foundation [bio]
1:40 –2:00A Proof-of-Concept Clinical Research Study of Efavirenz in Patients with Alzheimer's Disease
Irina Pikuleva, PhD—Case Western Reserve University [bio]
2:00–2:10Q&A
2:10–2:30Safety and Efficacy of Nabilone in Patients with Moderate to Severe Alzheimer's Disease: A Pilot Study
Krista Lanctôt, PhD—Sunnybrook Research Institute, University of Toronto [bio]
2:30–2:40Q&A
2:40–3:00Dopaminergic Therapy for Alzheimer's Disease Patients
Giacomo Koch, MD, PhD—Santa Lucia Foundation [bio]
3:00–3:10Q&A
3:10-3:30Phase 1 Study of the Putative Cognitive Enhancer VU319, a Muscarinic M1Positive Allosteric Modulator for Alzheimer's Disease
Paul Newhouse, MD—Vanderbilt University Medical Center [bio]
3:30-3:40Q&A
3:40-4:00Evaluating the Effects of the Novel GLP-I Analogue, Liraglutide, in Patients with Alzheimer’s Disease (ELAD Study)
Paul Edison, MD, MRCP, PhD, FRCPI—Imperial College London [bio]
4:00-4:10Q&A
4:10-4:20pmClosing Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation